Arcutis Biotherapeutics
ARQT
139 hedge funds and large institutions have $1.13B invested in Arcutis Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 19 reducing their positions, and 11 closing their positions.
1,579% more call options, than puts
Call options by funds: $5.86M | Put options by funds: $349K
258% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 19
218% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 11
21% more funds holding
Funds holding: 115 → 139 (+24)
8% more capital invested
Capital invested by funds: $1.05B → $1.13B (+$88.4M)
3.17% more ownership
Funds ownership: 95.44% → 98.61% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$40.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$28.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$22.7M |
| 5 |
Jennison Associates
New York
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$44.9M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$13.3M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.32M |
ARQT Hedge Fund Activity: Q3 2022 in Review
139 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2022, worth a combined $1.13B — up 8.5% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ARQT positions and 11 closed out — a net gain of 24 holders — while 68 added to existing stakes and 19 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $40.7M. The largest seller was OrbiMed, cutting an estimated $44.9M.
- 139 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2022, up from 115 in Q2 2022.
- Funds reported $1.13B of Arcutis Biotherapeutics stock for Q3 2022, up 8.5% quarter-over-quarter.
- 35 funds opened new Arcutis Biotherapeutics positions in Q3 2022 and 11 closed out, a net change of +24 holders.
- The largest Arcutis Biotherapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $40.7M added.
- The largest Arcutis Biotherapeutics seller in Q3 2022 was OrbiMed, an estimated $44.9M sold.
Based on aggregated 13F filings for Q3 2022.